Mutant TEM β-Lactamase Producing Resistance to Ceftazidime, Ampicillins, and β-Lactamase Inhibitors

Sergei Vakulenko and Dasantila Golemi

Departments of Biochemistry and Molecular Biology and Medicine, Wayne State University, Detroit, Michigan 48201, and Department of Chemistry, Wayne State University, Detroit, Michigan 48202

Received 17 May 2001/Returned for modification 23 September 2001/Accepted 23 November 2001

A derivative of the TEM-1 β-lactamase producing clinically significant levels of resistance to ceftazidime and β-lactamase inhibitors in the presence of penicillins was generated following five rounds of DNA shuffling and selection. This complex mutant enzyme contained three amino acid substitutions including those of residues 104 and 276 that are known to produce extended-spectrum resistance and, correspondingly, resistance to β-lactamase inhibitors. Although the Glu104Lys substitution by itself produced low levels of ceftazidime resistance, additional amino acid replacements in the enzyme with the triple mutation resulted in further enhancement of resistance to ceftazidime. Kinetic studies of the purified β-lactamase enzyme with the triple mutation indicated enhancement of the catalytic efficiency for turnover (kcat/Km) of ceftazidime. The increases in the K_m values of both clavulanic acid and tazobactam for the enzyme with the triple mutation were consistent with the observed bacterial resistance to the reversibility of β-lactam resistance with these inhibitors.

Five decades after their discovery, β-lactams, like penicillins and cephalosporins, are still the most widely used antibiotics for treatment of nosocomial and community-acquired infections. The emergence and subsequent wide dissemination of bacteria that are resistant to a variety of β-lactam antibiotics pose a serious threat to the future effective use of these antimicrobial agents (9, 30). Notwithstanding the fact that several mechanisms could be implicated, the principal mechanism of resistance to β-lactams in clinical bacterial isolates is the production by these organisms of specific enzymes, β-lactamases of four functional classes: classes A, B, C, and D (8).

Class A β-lactamases are the most common among clinical isolates. Major representative members of the class A β-lactamases in gram-negative microorganisms are the TEM and SHV types, which are most common in Escherichia coli and Klebsiella pneumoniae (20). In the 1970s and 1980s, novel β-lactams, such as the expanded-spectrum cephalosporins, were developed to counter the growing problem of β-lactamase-mediated β-lactam resistance in gram-negative bacilli. Since the expanded-spectrum cephalosporins are poor substrates for the prototypic TEM or SHV enzymes, they retain excellent activity against bacteria producing these β-lactamases. Another strategy used to overcome resistance to penicillins mediated by class A β-lactamases has been the development of β-lactamase inhibitors, such as clavulanic acid, sulbactam, and tazobactam. These β-lactam drugs have poor antibacterial activities by themselves. However, they covalently bind to the active sites of class A β-lactamases and inhibit them. Therefore, β-lactamase inhibitors in combination with penicillins are active against penicillin-resistant bacteria.

Under selective pressure from the use of expanded-spectrum cephalosporins in the 1980s and 1990s, bacteria have evolved to overcome the threat of these drugs. Strains resistant to expanded-spectrum cephalosporins have emerged (12, 34). These strains typically bear the TEM- or SHV-type β-lactamases with improved activity against expanded-spectrum β-lactams. These so-called extended-spectrum β-lactamases (ESBLs) were found to have from one to a few amino acid substitutions at positions 104, 164, 238, and 240 (11, 21, 23, 27, 28, 42). The TEM and SHV β-lactamases have also evolved in response to the use of β-lactamase inhibitors. Multiple clinical isolates resistant to penicillin–β-lactamase inhibitor combinations have been reported (2, 6, 10, 19, 25). Examination of the β-lactamase genes has revealed that replacement of one of four different amino acid residues in the enzyme is responsible for the resulting phenotype (5, 18, 32, 36). Substitutions at critical residues at positions 69, 130, 244, and 276 were able to produce the inhibitor-resistant TEM (IRT) phenotype by themselves (1–3, 14) or in combination with other replacements (7, 18, 44). Thus, the parental TEM-1 β-lactamase can readily evolve to resist inhibition or to confer a broadened β-lactam resistance spectrum, and such mutants are readily selected by growth in the presence of β-lactamase inhibitors or expanded-spectrum cephalosporins, respectively. Although several clinical isolates have been reported to combine both of these phenotypes, none of them produce clinically significant levels of resistance to both β-lactamase inhibitors and expanded-spectrum cephalosporins.

In the study described here we used shuffling of the TEM-1 β-lactamase gene to construct mutant enzymes that would produce resistance to both expanded-spectrum cephalosporins and β-lactamase inhibitors. DNA shuffling is a powerful technique that allows one to randomly recombine multiple mutations introduced by PCR, thus mimicking and dramatically accelerating evolution. Mutant enzyme that contained three amino acid substitutions and that expressed the double ESBL and IRT phenotype was selected. The contributions of individual mutations to the resistance phenotype were evaluated.

(This work was previously presented in part at the 39th...

MATERIALS AND METHODS

Bacterial strains and media. E. coli JM38 (F− ara D (lac-pro-AB) gyr. (Str+) [800 dlac Δ (lac-Z/M15)] thi) was used as the recipient strain for plasmids and as the host for the determination of susceptibilities to antibiotics (New England Biolabs). E. coli BMH 71-18 mutS (thr supE Δ (lac-pro-AB) mutS[S::Tn 10]) was used as the intermediate host in site-directed mutagenesis experiments (Clontech). E. coli BL21(DE3) [F omp T hsdS (r B− m B− g col dcM (DE3))] was the host for target gene expression (Novagen). Luria-Bertani (LB) medium. Mueller-Hinton broth, or Terrific Broth (Difco) was used as the growth medium for all bacterial strains. Bacto Agar (Difco) was added at a concentration of up to 1.5% for the preparation of solid medium.

Reagents, antibiotics, and susceptibility testing. Restriction endonucleases, DNA-modifying enzymes, T4 DNA polymerase, and Taq DNA polymerase were purchased from New England Biolabs or BRL. Pfu Turbo DNA polymerase was purchased from Stratagene; and DNaseI was purchased from Sigma. Inorganic chemicals were from Sigma or Gibco BRL. Plasmid DNA was isolated with a Qiagen; and PCR products were removed from the PCR product with the QIAquick PCR purification kit (Qiagen). 300 to 400 ng of DNA of the β-lactamase gene was recloned into the plTZ19−3 vector. The resulting construct was used to electroporate competent E. coli JM38 cells, and mutants were selected for resistance to ceftazidime. To eliminate mutations that are not related to the resulting phenotype, we performed the so-called back-shuffling procedure when the DNA of mutant 1 has been reshuffled with a large excess (20 times) of wild-type DNA.

Construction of mutant β-lactamases. The enzyme with the triple mutation Glu104Lys, Ser268Gly, and Asn276Asp was constructed by substituting the following fragment of pTz19−3 620-bp Kpn−BanHI fragment in mutant 6 for the same fragment from the gene for the wild-type enzyme. Substitutions Lys104 for Glu104, Glu268 for Ser268, and Asp276 for Asn276 in the TEM−1 β-lactamase were introduced by site-directed mutagenesis of the TEM−1 β-lactamase gene of plasmid pTz19−4 by using the following mutagenic primers: primer Glu104Lys (GAA TACGGTGTTGGA ATACTACGGAGTCG AGAACATATG), primer Ser268Gly (CT ACAGAACGGGGGTCGG CAAACTATG), and primer Asn276Asp (CT ATGGTGAAAGAGGAT GAGCG), respectively. All combinations of amino acid substitutions in the TEM−1 β-lactamase were constructed by combining the various restriction fragments of the TEM β-lactamase gene containing individual mutations. Specifically, the mutants with the Glu104Lys and Ser268Gly double mutation was constructed by ligating the ~620-bp Pst−BanHI fragment from the plTZ19−3 derivative that contains a mutation that results in the Glu104Lys substitution with the large Pst−BanHI fragment of another plTZ19−3 derivative that contains a mutation that results in the Ser268Gly substitution in the TEM−1 β-lactamase. Similarly, the mutant with the Glu104Lys and Asn276Asp double mutation was constructed by ligating the ~620 bp Pst−BanHI fragment that contains a mutation that results in the Glu104Lys substitution with the large Pst−BanHI fragment of another plTZ19−3 derivative that contains a mutation that results in the Asn276Asp substitution in the TEM−1 β-lactamase. The mutant with the double Ser268Gly and Asn276Asp replacements was constructed by replacing the ~620-bp Pst−BanHI fragment in mutant 2 (that was obtained in the course of shuffling the TEM−1 β-lactamase gene) with the Pst−BanHI fragment of the TEM−1 β-lactamase gene.

Cloning of TEM β-lactamase genes into expression vector. To facilitate β-lactamase secretion into the growth medium, we fused the genes for the mature TEM−1 β-lactamase and the β-lactamases with triple mutations with the leader sequence of the OmpA protein. DNA fragments encoding the mature TEM−1 β-lactamase were amplified from plasmid pTz19−3 by 20 cycles of high-fidelity PCR with Pfu Turbo DNA polymerase. Two primers, primer TEM-Mdir (GACCCGAGAAGCGGTGTTG) and primer TEM-Mrev (GAGTAAGCTTGGTGCTGAC), were used for this purpose. PCR products were purified from the agar gel, digested with HindIII, and ligated into the Nde−HindIII sites of pStV106. The entire TEM β-lactamase genes and the OmpA leader were sequenced. TEM β-lactamase genes were cut out with the Nde−HindIII restriction endonucleases, cloned into the Nde−HindIII sites of expression vector pET24a, and introduced by transformation into the recipient strain, E. coli BL21(DE3).

DNA sequencing. Sequencing of the double-stranded plasmid DNA was performed with the Sequenase DNA sequencing kit (version 2.0, U.S. Biochemicals) and a set of custom-made internal primers by the procedure described by manufacturer.

Purification of TEM β-lactamases. For enzyme purification, overnight cultures of E. coli BL21(DE3) in LB medium supplemented with kanamycin at 20 μg/ml were diluted 100-fold in Terrific Broth (Difco) supplemented with 20 μg of kanamycin per ml. 0.5 M sorbitol, and 2.5 mM betaine. After 4 to 5 h of incubation with shaking (280 to 280 rpm) at 37°C (until the optical density of the culture at 600 nm reached 0.6), isopropyl-β-D-thiogalactopyranoside was added to a final concentration 0.4 mM and the cultures were incubated overnight at 25°C. The cells were pelleted by centrifugation, and the supernatants containing the enzyme were concentrated with an Amicon ultrafiltration device (membrane molecular weight cutoff, 10,000). Concentrated proteins were reconstituted in 0.01 M Tris buffer (pH 7.0) and loaded onto a DEAE anion-exchange column (Sigma) equilibrated with the same buffer. The enzymes were eluted by a linear gradient (10 mM Tris-100 mM Tris) and were homogeneous, as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Coomassie brilliant blue staining.

Determination of amounts of active enzymes. Cells producing the wild-type β-lactamase and the β-lactamase with the triple mutations were grown at 37°C overnight in LB broth supplemented with 30 μg of kanamycin per ml. After
20-fold dilution into the same medium, cells were grown for another 2 h and the cell density was adjusted spectrophotometrically at 600 nm. The cells were pelleted by centrifugation, suspended in 100 mM sodium phosphate buffer (pH 7.0), and subjected to sonication. The cell debris was then removed by centrifugation at 20,000 × g. Enzyme concentrations were determined from the rates of hydrolysis of ampicillin at a saturating concentration.

Enzyme kinetics. β-Lactamase activity against ampicillin and ceftazidime and the inhibition profile with clavulanic acid and tazobactam were determined spectrophotometrically with a Hewlett-Packard 8453 diode array spectrophotometer in 100 mM phosphate buffer (pH 7.0) at room temperature. Calculations of kinetic constants were performed with Microsoft Excel software. The hydrolysis of the β-lactam bond was monitored at 240 nm for ampicillin (Δε = 538 M⁻¹ cm⁻¹) and at 260 nm for ceftazidime (Δε = 10,500 M⁻¹ cm⁻¹). Kinetic parameters for the substrates were determined by the Hanes-Wolf method or with the integrated Michaelis-Menten equation (13).

Determination of the inhibition parameters was carried out by monitoring the hydrolysis of penicillin G at 240 nm (Δε = 570 M⁻¹ cm⁻¹) at room temperature in 100 mM sodium phosphate buffer (pH 7.0). These experiments were performed under conditions of excess substrate concentrations, as described by Koerber and Fink (24).

Inactivation rate constants for clavulanic acid and tazobactam with both the wild-type and mutant enzymes were calculated as described previously (40). Enzyme (1.6 μM) and inhibitor (200 to 800 μM for clavulanic acid and 20 to 160 μM for tazobactam) were incubated at 4°C, and at appropriate times small aliquots were removed from this mixture and diluted 50 times to an assay mixture containing 2 mM penicillin G. The highest steady-state rates during the course of substrate hydrolysis were used to calculate the remaining activity.

The dissociation constants (Kᵢ) of clavulanic acid and tazobactam for the wild-type enzyme and the enzyme with the triple mutation were calculated by the method of Dixon (15). Two concentrations of the penicillin G substrate were used, and a series of assay mixtures containing both the substrate and inactivators at various concentrations (2 to 24 μM for clavulanic acid and 0.4 to 2 μM for tazobactam) were prepared in 100 mM sodium phosphate buffer (pH 7.0). An aliquot of the stock solution of the inhibitor was added to obtain final concentrations of 0.6 mM for both the wild-type enzyme and the enzyme with triple mutations, followed by the immediate measurement of enzyme activity. Rates were measured for the first 5% of substrate turnover.

Partition ratios (kₑₜₐₜ₉ₑₜₐₜ [where kₑₜₐₜ₉ₑₜₐₜ is the rate constant for inactivation]) for clavulanic acid and tazobactam were determined for both enzymes by the titration method (33). Several buffered mixtures containing various molar ratios ([I]/[E]) of each of the inhibitors (I) with each of the enzymes (E) were incubated at 4°C overnight (ca. 20 h). The molar ratio ([I]/[E]) for clavulanic acid varied from 1 to 200 for the wild-type enzyme and 1 to 500 for the mutant enzyme. For tazobactam the molar ratio varied from 1 to 400 for the wild-type enzyme and 1 to 600 for the mutant enzyme. The remaining activity of the enzyme was assayed under conditions of excess penicillin G (2 mM).

Rate constants for the recovery of enzyme activity (kₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑₑ等症状
numbers of amino acid substitutions in the TEM β-lactamase gene than mutant 1 (Table 1, mutants 2 to 6). The mutants that we obtained by back-shuffling were checked not only for their susceptibilities to ceftazidime and other β-lactam antibiotics but also for the reversibility of ampicillin and ceftazidime resistance by clavulanic acid. As seen in Table 2, all of the mutants retained resistance to ceftazidime alone and in combination with clavulanic acid, but for most mutants the ceftazidime MICs were lower than that for mutant 1. Mutants 2, 3, and 6 regained high-level resistance to ampicillin. In addition, mutant 6 was the only one that had a high level of resistance to ampicillin in the presence of clavulanic acid.

Construction of specific mutant enzymes and susceptibility testing. In order to further minimize the number of mutations in the TEM-1 β-lactamase, the enzyme with the triple mutation (E104K, S268G, N276D) was first constructed. Although the ampicillin and ceftazidime MICs for this mutant were two-fold lower than those for the mutant with quintuple mutations (mutant 6), its level of resistance to ampicillin paralleled that produced by the TEM-1 β-lactamase and its level of resistance to ceftazidime was 16 times higher (Table 3). On the basis of the amino acid sequence of the enzyme with triple mutations, six additional mutant TEM β-lactamases were constructed (see experimental procedures above) to evaluate the contributions of individual amino acid substitutions and their combinations to the resulting resistance (Table 3).

All mutant β-lactamases exhibited high-level resistance to both ampicillin and piperacillin comparable to that conferred by the parental TEM-1 enzyme (Table 3). On the other hand, the levels of susceptibility to ceftazidime varied among these mutants. The Glu104Lys mutation resulted in a fourfold higher ceftazidime MIC, and the additional presence of Ser268Gly or Asn276Asp enhanced the level of resistance further. The presence of both of the latter mutations together with Glu104Lys in the enzyme with the triple mutation raised the ceftazidime MICs even further. The variations of the MICs of cefepime paralleled the ceftazidime MIC profiles for the mutant strains, although the actual MICs of cefepime were generally lower. For ceftriaxone, cefotaxime, and aztreonam, the only mutant for which there was more than a fourfold rise in the MIC from the low MICs conferred by the parental TEM-1 β-lactamase was that with the Glu104Lys and Ser268Gly substitutions, and the resulting MICs were still only 1 μg/ml for all three antibiotics. The virtual absence of resistance to imipenem conferred by the TEM-1 enzyme was not affected by any of the mutations that we examined.

As expected, the presence of either clavulanic acid or tazobactam reduced the MICs of ampicillin and piperacillin conferred by the TEM-1 β-lactamase (Table 4). These reductions of the MICs were enhanced by the presence of the Glu104Lys mutation in the enzyme with a single mutation. The presence of the Asn276Asp mutation, either alone or in the presence of other mutations, reduced the effect of the β-lactamase inhibitors in enhancing susceptibility to ampicillin and piperacillin. Since the Glu104Lys mutation produced resistance to ceftazidime, the effects of the inhibitors on ceftazidime susceptibility could be studied in the mutants bearing this mutation. Thus, the modest level of resistance to ceftazidime conferred by the

### TABLE 2. MICs of β-lactams conferred by TEM-1 and its mutant derivatives

<table>
<thead>
<tr>
<th>Strains producing TEM-1 and mutant β-lactamases</th>
<th>AMP</th>
<th>AMP + CLA</th>
<th>CAZ</th>
<th>CAZ + CLA</th>
<th>FEP</th>
<th>CTX</th>
<th>CRO</th>
</tr>
</thead>
<tbody>
<tr>
<td>None (E. coli JM83)</td>
<td>4</td>
<td>2</td>
<td>0.06</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
</tr>
<tr>
<td>TEM-1</td>
<td>16,000</td>
<td>250</td>
<td>0.5</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Mutant 1</td>
<td>64</td>
<td>32</td>
<td>250</td>
<td>16</td>
<td>2</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Mutant 2</td>
<td>8,000</td>
<td>250</td>
<td>128</td>
<td>8</td>
<td>2</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Mutant 3</td>
<td>8,000</td>
<td>250</td>
<td>128</td>
<td>8</td>
<td>2</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Mutant 4</td>
<td>32</td>
<td>16</td>
<td>250</td>
<td>8</td>
<td>2</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Mutant 5</td>
<td>32</td>
<td>16</td>
<td>128</td>
<td>8</td>
<td>2</td>
<td>0.25</td>
<td>0.25</td>
</tr>
<tr>
<td>Mutant 6</td>
<td>32,000</td>
<td>4,000</td>
<td>64</td>
<td>16</td>
<td>0.25</td>
<td>0.12</td>
<td>0.06</td>
</tr>
</tbody>
</table>

a Abbreviations: AMP, ampicillin; CLA, clavulanic acid (at 2 μg/ml); CAZ, ceftazidime; FEP, cefepime; CTX, cefotaxime; and CRO, ceftriaxone.

### TABLE 3. MICs of various antibiotics conferred by mutant TEM β-lactamases

<table>
<thead>
<tr>
<th>Amino acid replacement(s)</th>
<th>AMP</th>
<th>PIP</th>
<th>CAZ</th>
<th>FEP</th>
<th>CRO</th>
<th>CTX</th>
<th>ATM</th>
<th>IPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. coli JM83 b</td>
<td>4</td>
<td>1</td>
<td>0.06</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>0.12</td>
</tr>
<tr>
<td>TEM-1 (none) f</td>
<td>16,000</td>
<td>4,000</td>
<td>0.5</td>
<td>0.25</td>
<td>0.06</td>
<td>0.06</td>
<td>0.12</td>
<td>0.12</td>
</tr>
<tr>
<td>E104K</td>
<td>16,000</td>
<td>2,000</td>
<td>2</td>
<td>0.5</td>
<td>0.25</td>
<td>0.25</td>
<td>0.5</td>
<td>0.12</td>
</tr>
<tr>
<td>S268G</td>
<td>16,000</td>
<td>4,000</td>
<td>0.5</td>
<td>0.5</td>
<td>0.12</td>
<td>0.12</td>
<td>0.12</td>
<td>0.12</td>
</tr>
<tr>
<td>N276D</td>
<td>16,000</td>
<td>4,000</td>
<td>0.5</td>
<td>0.25</td>
<td>0.03</td>
<td>0.03</td>
<td>0.06</td>
<td>0.12</td>
</tr>
<tr>
<td>E104K, S268G</td>
<td>16,000</td>
<td>4,000</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.12</td>
</tr>
<tr>
<td>E104K, N276D</td>
<td>16,000</td>
<td>2,000</td>
<td>4</td>
<td>1</td>
<td>0.06</td>
<td>0.06</td>
<td>0.25</td>
<td>0.12</td>
</tr>
<tr>
<td>S268G, N276D</td>
<td>16,000</td>
<td>4,000</td>
<td>1</td>
<td>0.5</td>
<td>0.03</td>
<td>0.03</td>
<td>0.06</td>
<td>0.12</td>
</tr>
<tr>
<td>E104K, S268G, N276D</td>
<td>16,000</td>
<td>4,000</td>
<td>8</td>
<td>2</td>
<td>0.12</td>
<td>0.12</td>
<td>0.25</td>
<td>0.12</td>
</tr>
<tr>
<td>A42G, I47V, E104K, S268G, N276D</td>
<td>32,000</td>
<td>8,000</td>
<td>16</td>
<td>4</td>
<td>0.25</td>
<td>0.25</td>
<td>0.5</td>
<td>0.12</td>
</tr>
</tbody>
</table>

a Abbreviations: AMP, ampicillin; PIP, piperacillin; CAZ, ceftazidime; FEP, cefepime; CRO, ceftriaxone; CTX, cefotaxime; ATM, aztreonam; IPM, imipenem.

b Recipient strain E. coli JM83.

f Wild-type TEM-1 β-lactamase.

Downloaded from http://aac.asm.org/ on May 16, 2021 by guest
concentrations (in micrograms per milliliter).

The presence of clavulanic acid (2 or 4 mg/ml) allowed us to isolate 40 mg of soluble TEM-1 and 30 mg of the β-lactamase with the triple mutation against ceftazidime was 6.3 times higher than that of TEM-1. On the other hand, the catalytic efficiency of the enzyme with the triple mutation against ceftazidime was 6.3 times higher than that of TEM-1.

Table 6 presents the effects of clavulamic acid and tazobactam on the purified β-lactamase with the triple mutation and the TEM-1 β-lactamase. The $K_i$ values of clavulamic acid were 7.8-fold higher for the enzyme with the triple mutation than for the wild-type enzyme, and those of tazobactam were comparable for both enzymes. With clavulamic acid the partition ratio ($k_{cat}/K_{inact}$) of the enzyme with the triple mutation was 2.7 times higher than that of the TEM-1 β-lactamase, and with tazobactam it was only slightly (18%) higher than that of the TEM-1 β-lactamase.

**DISCUSSION**

Our approach to the question of whether a TEM-derived mutant β-lactamase could confer extended-spectrum β-lactam resistance and resistance to β-lactamase inhibitors was based on the ability to generate numerous random mutations by PCR.

---

**TABLE 4. Susceptibilities of E. coli JM83 producing TEM-1 and its mutants to β-lactams and to β-lactam–β-lactamase inhibitor combinations**

<table>
<thead>
<tr>
<th>Amino acid replacement(s)</th>
<th>MICs (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AMP</td>
</tr>
<tr>
<td>TEM-1 (none)</td>
<td>16,000</td>
</tr>
<tr>
<td>E104K</td>
<td>16,000</td>
</tr>
<tr>
<td>S268G</td>
<td>16,000</td>
</tr>
<tr>
<td>N276D</td>
<td>16,000</td>
</tr>
<tr>
<td>E104K, S268G</td>
<td>16,000</td>
</tr>
<tr>
<td>E104K, N276D</td>
<td>16,000</td>
</tr>
<tr>
<td>S268G, N276D</td>
<td>16,000</td>
</tr>
<tr>
<td>E104K, S268G, N276D</td>
<td>16,000</td>
</tr>
<tr>
<td>A42G, I47V, E104K, S268G, N276D</td>
<td>32,000</td>
</tr>
</tbody>
</table>

a Abbreviations: AMP, ampicillin; CLA, clavulamic acid; TAZ, tazobactam; PIP, piperacillin; CAZ, ceftazidime. The numbers after the abbreviation’s indicate concentrations (in micrograms per milliliter).

b Wild-type TEM-1 β-lactamase.
TABLE 6. Inhibition profiles of wild-type β-lactamase and β-lactamase with triple mutations for clavulanic acid and tazobactam

<table>
<thead>
<tr>
<th>β-Lactamase</th>
<th>Inhibitor</th>
<th>$k_{inact}$ ($s^{-1}$)</th>
<th>$K_i$ (µM)</th>
<th>$k_{cat}$/$k_{inact}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>Clavulanate</td>
<td>0.4 ± 0.1</td>
<td>1.4 ± 0.3</td>
<td>180 ± 30</td>
</tr>
<tr>
<td></td>
<td>Tazobactam</td>
<td>1.1 ± 0.6</td>
<td>0.014 ± 0.003</td>
<td>550 ± 120</td>
</tr>
<tr>
<td>Mutant</td>
<td>Clavulanate</td>
<td>0.36 ± 0.01</td>
<td>11 ± 1</td>
<td>480 ± 7</td>
</tr>
<tr>
<td></td>
<td>Tazobactam</td>
<td>0.72 ± 0.07</td>
<td>0.018 ± 0.002</td>
<td>650 ± 18</td>
</tr>
</tbody>
</table>

mutagenesis and to randomly recombine them by DNA shuffling (38). DNA shuffling is known to be a powerful mutagenic technique that creates numerous combinations of mutations in a gene of interest, thus mimicking evolution and accelerating it in an observable time frame (39, 43). We first produced a pool of mutant TEM β-lactamase genes with numerous combinations of mutations that would produce high levels of resistance to ceftazidime. We anticipated that subsequent selection on ceftazidime or ampicillin in combination with the β-lactamase inhibitors would allow us to obtain the desired mutants with a double ESBL-IRT phenotype.

Mutant 1, generated by five successful rounds of DNA shuffling and selection, is a complex β-lactamase that combines three amino acid substitutions of the ESBL type (Glu104Lys, Gly238Ser, and Glu240Gly) with an IRT-specific mutation (Asn276Asp). It confers high levels of resistance to ceftazidime alone and in combination with clavulanic acid. On the other hand, mutant 1 produces very low levels of resistance to ampicillin. Analysis of amino acid substitutions in five derivatives of mutant 1 (mutants 2 to 6) suggests that the proline-for-leucine substitution at position 169 may be responsible for the loss of ampicillin resistance. Thus, all derivatives of mutant 1 with Leu169Pro substitutions (mutants 4 and 5) produce low levels of ampicillin resistance, while those with leucine at position 169 (mutants 2, 3, and 6) produce high levels of ampicillin resistance. At the same time, the Leu169Pro substitution in mutant 2 produces an eightfold increase in the level of resistance to ceftazidime in comparison to that of mutant 6, which lacks this mutation (Tables 1 and 2). As has been shown previously (26), some substitutions at position 169 in combination with other adjacent mutations in the omega loop of the TEM-1 β-lactamase could produce resistance to ceftazidime, with a concomitant significant compromise in the resistance to ampicillin. Also, the Leu169Pro substitution by itself has not previously been shown to be able to confer such a phenotype, and our results support previous data showing the importance of residue 169 in ceftazidime and ampicillin resistance. On the other hand, poor levels of expression of TEM β-lactamases with substitutions at positions 161 to 170 could prevent the Leu169Pro mutation from appearing in clinical isolates (26).

Although mutant 1 and all its derivatives (mutants 2 to 6) produce high levels of resistance to ceftazidime and significant levels of resistance to ceftazidime in the presence of clavulanic acid, only mutant 6 conferred a high level of resistance to the combination ampicillin and clavulanic acid (Table 2). Analysis of the amino acid sequences of mutants 1 to 6 showed that they all possess the Glu104Lys substitution, which provides only an insignificant increase in the level of resistance to ceftazidime by itself. Mutants 1 to 5, in addition, harbor at least one of the four other mutations (Pro167Ser, Leu169Pro, Gly238Ser, Glu240Gly) that are able, by themselves, to produce high-level resistance to ceftazidime. Analysis of data from various studies indicates that combinations of such mutations that produce an ESBL phenotype with high-level resistance with mutations that produce the IRT phenotype results in complex enzymes that are able to express only one of these phenotypes (4, 22, 37). Similarly, mutants 1 to 5 produce resistance only to ceftazidime. Among the amino acid substitutions that are present in the enzyme with the triple mutation, Glu104Lys is the only one that is known to produce the ESBL phenotype, and Asn276Asp is the only one that produces the IRT phenotype. While the β-lactam-β-lactamase inhibitor resistance produced by the Asn276Asp substitution alone is clinically important, the Glu104Lys substitution produces only a low level of ceftazidime resistance. The other two replacements, Ser268Gly and Asn276Asp, which are neutral by themselves with respect to ceftazidime resistance, produce increases in the ceftazidime MICs when they are individually combined with Glu104Lys and especially produce increases in the ceftazidime MICs when they are both combined with Glu104Lys to produce the enzyme with the triple mutation. The enzyme with the quintuple mutation, which has two additional amino acid substitutions, Ala42Gly and Ile47Val, conferred another twofold rise in the MICs of ampicillin, piperacillin, and ceftazidime. The roles of these additional mutations merit further exploration.

In the presence of clavulanic acid (2 µg/ml), the ceftazidime MICs conferred by the enzyme with the triple mutation were lower than those in the absence of the inhibitor but were still eight times higher than that for the TEM-1-producing E. coli strain. Thus, the presence of clavulanic acid produced a relative decline of only one dilution in the ratios of the ceftazidime MICs conferred by the enzyme with the triple mutation to that conferred by TEM-1. In addition, the enzyme with the triple mutation produced higher ampicillin-clavulanic acid and piperacillin-tazobactam MICs, as well as higher ampicillin-tazobactam and ceftazidime-tazobactam MICs (Table 4).

On the enzymologic level, the increased catalytic efficiency of the enzyme with the triple mutation for ceftazidime in comparison with that of TEM-1 was consistent with the increase in the ceftazidime MIC. However, the decline in the catalytic efficiency of this enzyme for ampicillin was not reflected in the MICs of ampicillin conferred by the two enzymes. These differences could in part be explained by the higher level of expression of the enzyme with the triple mutation, as enzyme stability does not seem to be an issue in this case. Also, susceptibility testing with the conventional twofold dilutions might not reveal small differences. The increases in the $K_i$ values of both clavulanic acid and tazobactam for the β-lactamase with the triple mutation are consistent with the observed resistance to the reversibility of β-lactam resistance with these inhibitors.
in cell cultures. The partition ratios of the enzyme with the triple mutation with both clavulanic acid and tazobactam were greater than those of TEM-1, although the increase for tazobactam was quite modest.

Three clinical isolates (16, 29, 35) and several laboratory mutants (22, 37) that produce the so-called complex β-lactamases have been described to date. These complex enzymes possess, in various combinations, both the amino acid substitutions that produce extended-spectrum antibiotic and inhibitor resistance. All resultant mutant β-lactamases, with one exception, produce only one of the two resistance phenotypes. The only enzyme that conferred both the ESBL and the IRT phenotypes had the following combination of amino acid substitutions: Arg164Ser, Met69Leu, and Asn276Asp. This complex β-lactamase produces significant resistance to ceftazidime and, to some extent, to inhibition by clavulanic acid. At the same time the enzyme became susceptible to inhibition by TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β-lactam-producing klebsiellae. Antimicrob. Agents Chemother. 39:427–430.


34. Sirot, D. 1995. Extended-spectrum plasmid-mediated β-lactamases. J. Antimi-
Labia, and J. Sirot. 1997. A complex mutant of TEM-1 β-lactamase with
mutations encountered in both IRT-4 and extended-spectrum TEM-15, pro-
41:1322–1325.
1995. Incidence and mechanisms of resistance to the combination of amoxi-
39:2478–2483.
characterization of mutants of the TEM-1 β-lactamase containing amino
acid substitutions associated with both extended-spectrum resistance and
resistance to β-lactamase inhibitors. Antimicrob. Agents Chemother. 43:
1881–1887.
38. Stemmer, W. P. C. 1994. DNA shuffling by random fragmentation and
Acad. Sci. USA 91:10747–10751.
40. Swaren, P., D. Golemi, S. Cabantous, A. Bulychev, L. Maveyraud, S. Mob-
bashery, and J. P. Samama. 1999. X-ray structure of the Asn276Asp variant
of the Escherichia coli TEM-1 β-lactamase: direct observation of electro-
static modulation in resistance to inactivation by clavulanic acid. Biochem-
istry 38:9570–9576.
1998. Selection and characterization of β-lactam-β-lactamase inactivator-
resistant mutants following PCR mutagenesis of the TEM-1 β-lactamase
42. Vakulenko, S. B., P. Taibi-Tronche, M. Toth, I. Massova, S. A. Lerner, and
S. Mobashery. 1999. Effects on substrate profile by mutational substitutions
at positions 164 and 179 of the class A TEMpUC19 β-lactamase from Esch-
43. Yano, T., and H. Kagamiyama. 2001. Directed evolution of ampicillin-resis-
tant activity from a functionally unrelated DNA fragment: a laboratory
Emergence of clinical isolates of Escherichia coli producing TEM-1 deriva-
tives or an OXA-1 β-lactamase conferring resistance to β-lactamase inhib-